Popular Trials
Alkylating agents
Cyclophosphamide + Sirolimus for Advanced Thyroid Cancer
This trial uses two drugs, Cyclophosphamide and Sirolimus, to treat patients with thyroid cancer that has spread. Cyclophosphamide kills cancer cells by breaking their DNA, while Sirolimus stops them from growing. Sirolimus has been used in various treatments and has shown effectiveness against different cancers. Patients are monitored for side effects and effectiveness.
Popular Filters
Trials for Thyroid Gland Carcinoma Patients
MEK Inhibitor
Trametinib for Thyroid Cancer
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
Trials for Thyroid Nodule Patients
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
Trials for Metastatic Patients
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
Kinase Inhibitor
Everolimus + Sorafenib for Thyroid Cancer
This trial is testing a combination of two pills, sorafenib and everolimus, to treat thyroid cancer. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. Everolimus is approved for various cancers, including breast cancer, and has shown promise in combination therapies. The study aims to see if this combination works better than current treatments.
MEK Inhibitor
Selumetinib + Olaparib for Cancer
This trial has two phases: in the first, they'll find the highest dose of the drugs that patients can tolerate; in the second, they'll see if that dose can help control patients' advanced or recurrent solid tumors. Safety will also be monitored in both phases.
Trials for BRAF Positive Patients
MEK Inhibitor
Trametinib for Thyroid Cancer
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
MEK Inhibitor
Selumetinib + Olaparib for Cancer
This trial has two phases: in the first, they'll find the highest dose of the drugs that patients can tolerate; in the second, they'll see if that dose can help control patients' advanced or recurrent solid tumors. Safety will also be monitored in both phases.
Monoclonal Antibodies
Atezolizumab + Chemotherapy for Thyroid Cancer
This trial is testing a combination of atezolizumab and chemotherapy in patients with aggressive thyroid cancer. The treatment aims to boost the immune system and stop cancer cell growth. Atezolizumab helps enhance the immune response against cancer cells.
Trials for RET Positive Patients
Tyrosine Kinase Inhibitor
Selpercatinib for Solid Tumors
This trial is testing a new oral drug called selpercatinib in patients with advanced cancers that have specific gene changes. The drug aims to block a gene that helps cancer grow, potentially slowing or stopping the disease.
Tyrosine Kinase Inhibitor
Selpercatinib for Thyroid Cancer
This trial is looking at a new treatment option for patients with advanced papillary thyroid cancer after surgery. The current treatment, radioactive iodine therapy, is not always effective and has potential risks such as lung
Kinase Inhibitor
LOXO-260 for Non-Small Cell Lung Cancer
This trial is testing LOXO-260, a new drug for treating cancers with a specific genetic change in the RET gene. The drug aims to block this gene to stop cancer cells from growing. The study will check if the drug is safe and effective over a period of time. Selpercatinib (LOXO-292), a predecessor to LOXO-260, has shown marked and durable antitumor activity in patients with RET-altered tumors.
Phase 3 Trials
Kinase Inhibitor
Dabrafenib + Trametinib for Thyroid Cancer
This trial tests two drugs, dabrafenib and trametinib, on adults with a specific type of advanced thyroid cancer. These patients have a genetic mutation and have not responded to other treatments. The drugs work by blocking proteins that help cancer cells grow.
Tyrosine Kinase Inhibitor
Vandetanib for Thyroid Cancer
This trial is investigating the effects of the drug ZD6474 on patients with medullary thyroid cancer, in order to learn more about the drug's efficacy, side effects, and how it works in the human body.
Receptor Tyrosine Kinase Inhibitor
Targeted Therapy vs. Chemotherapy for Thyroid Cancer
This trial compares the effectiveness of cabozantinib versus a combination of dabrafenib and trametinib in treating patients with thyroid cancer that does not respond to treatment and has a specific
Trials With No Placebo
MEK Inhibitor
Trametinib for Thyroid Cancer
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
View More Related Trials
Frequently Asked Questions
Introduction to thyroid cancer
What are the top hospitals conducting thyroid cancer research?
When it comes to cutting-edge clinical trials in the realm of thyroid cancer, several renowned hospitals are leading the way. In New york City, Memorial Sloan Kettering Cancer Center is revolutionizing research with an impressive 21 active thyroid cancer trials. While they have not conducted any previous studies specifically focused on this condition, their dedication to exploring new treatments offers hope for patients and sets the stage for groundbreaking discoveries. Similarly, M D Anderson Cancer Center in Houston boasts 17 ongoing trials dedicated to advancing our understanding and treatment options for thyroid cancer.
Moving along the East Coast, Dana-Farber Cancer Institute in Boston is also making significant contributions with eight active clinical trials aimed at improving outcomes for those affected by thyroid cancer. Although this institution has not previously conducted any specific thyroid cancer studies, their commitment to innovation positions them as a force within the field.
In Houston's University of Texas MD Anderson Cancer Center and Rochester's Mayo Clinic, both institutions have begun delving into the world of thyroid cancer research more recently. With seven ongoing trials each at these hospitals, they are actively investigating new avenues and potential breakthroughs that may shape future treatment approaches. Both centers initially embarked on their pioneering journeys into this particular type of trial in 2017.
These top hospitals stand as beacons of hope for individuals battling against thyroid cancer across different locations throughout America; all united by a common goal: finding more effective treatments while striving towards improved patient outcomes . Their relentless pursuit of knowledge and dedication to medical advancements offer promise that one day we will conquer this complex disease
Which are the best cities for thyroid cancer clinical trials?
Houston, Texas; New york, New York; Los Angeles, California; Boston, Massachusetts; and Philadelphia, Pennsylvania are among the best cities for thyroid cancer clinical trials. These cities offer a significant number of active trials focused on investigating various treatments such as Pembrolizumab, cabozantinib, LOXO-292, pralsetinib (BLU-667), Vemurafenib, Nivolumab, and more. Through these trials, researchers aim to advance our understanding of thyroid cancer treatment options and potentially improve outcomes for patients facing this disease.
Which are the top treatments for thyroid cancer being explored in clinical trials?
[Thyroid cancer](https://www.withpower.com/clinical-trials/thyroid-cancer) research is rapidly advancing, with notable treatments emerging in current clinical trials. One such treatment is Vemurafenib, currently being explored in two active trials for thyroid cancer. Despite its recent entry into the scene in 2020, it has already shown promising potential with a total of two all-time clinical trials dedicated to this specific type of cancer. As researchers continue their diligent efforts, there is hope that Vemurafenib and other innovative treatments will pave the way towards improved outcomes for patients battling thyroid cancer.
What are the most recent clinical trials for thyroid cancer?
Recent clinical trials offer a beacon of hope for individuals battling thyroid cancer. Amongst the latest advancements is a Phase 2 trial aimed at patients with radioiodine-refractory, recurrent, and/or metastatic differentiated thyroid cancer (DTC). This study explores innovative treatment options to address this challenging subtype of thyroid cancer. Another trial focuses on DB-1202 Dose Expansion 3, which investigates potential therapeutic benefits in patients with thyroid cancer through both Phase 1 and Phase 2 stages. Additionally, a Phase 1 Dose Expansion trial showcases promising developments in the field by evaluating new approaches for treating thyroid cancer. These groundbreaking studies bring us closer to improved outcomes and enhanced care for those affected by this disease.
What thyroid cancer clinical trials were recently completed?
Recently completed clinical trials in the field of thyroid cancer have made significant strides towards advancing treatment options. Notably, a trial sponsored by the National Cancer Institute (NCI) investigated the efficacy of a novel targeted therapy and concluded successfully. The results are encouraging for patients with thyroid cancer as they offer potential avenues for improved management of this complex disease.